UCSD Spinout to Market Low-cost, Handheld qPCR Device for HAI Testing

Nascent firm DevaCell believes that its ScanStream instrument will cost a tenth the price of comparable commercial platforms and save the US healthcare system $5 billion to $10 billion per year by curbing the incidence of hospital-associated infections.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.